# Lilly's retatrutide meets Phase 3 goals in two more obesity trials, TRIUMPH-2 and TRIUMPH-3

Canonical page: https://technooptimist.io/stories/lilly-s-retatrutide-meets-phase-3-goals-in-two-more-obesity-trials-f3d04ff8
Date: 23 Jul 2026
About: [Eli Lilly](https://technooptimist.io/companies/eli-lilly.md) · [Retatrutide](https://technooptimist.io/biotech/retatrutide.md)
Original source: https://investor.lilly.com/node/54736

Lilly reports that its triple agonist retatrutide met the primary endpoint in TRIUMPH-2, in adults with type 2 diabetes and obesity, and in TRIUMPH-3, in severely obese adults with established heart disease. Weight loss at 80 weeks reached about 21% and 23% at the top doses. The drug is not approved anywhere; Lilly plans to file with the FDA in Q1 2027.

## Key facts

- TRIUMPH-2 (1,152 adults with type 2 diabetes): weight loss of 12.7%, 19.1% and 20.8% at 4, 9 and 12 mg after 80 weeks, against 4.0% on placebo.
- TRIUMPH-3 (1,949 adults with BMI 35 or more and cardiovascular disease): 21.6% and 22.6% at 9 and 12 mg after 80 weeks, against 3.2% on placebo.
- HbA1c fell 1.4 to 1.6 points in TRIUMPH-2 (from a 7.7% baseline), against 0.2 on placebo.
- Cardiovascular events in TRIUMPH-3 were not statistically significant (MACE-3 hazard ratio 1.12, 95% CI 0.64 to 1.96).
- Lilly is finishing the manufacturing data package before a BLA submission in Q1 2027; full results are not yet in a peer-reviewed journal.

---

The Techno Optimist tracks every frontier of technology, program by program: https://technooptimist.io/ (a Markdown version of any page: add .md to its URL; site map for agents: https://technooptimist.io/llms.txt).
Data API (JSON, realtime stream): https://technooptimist.io/developers. People read 5 pages free, then Reader $10/month; these Markdown pages are open to agents.